3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

Gut bacteria influence HIV reservoir size and activity differently across GI segments, offering insights for targeted cure ...

The following highlights spotlight the latest advances in gastroenterology, featuring studies and insights presented at this ...

Robust scale-down agitation models simulate mechanical stress essential for assessing and preventing protein aggregation in ...

STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm ...

On Tuesday, 1619 stocks advanced, 2540 declined and 177 remained unchanged on Bombay Stock Exchange with advance decline ...

Magnesium is essential for several bodily processes, including energy production, muscle and nerve health, and blood pressure regulation. Pairing it with certain supplements can help enhance its ...

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included ...

Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).